Our pipeline

CERo is building a broad pipeline of CER T-cell and dual-targeting (CER+CAR) T-cell products.

Lead program

Our lead program pairs CER T cells with a standard-of-care targeted small molecule inhibitor against B-cell lymphomas. In parallel, we are exploring additional hematologic and solid tumor indications, where CER T cells may provide enhanced benefits over existing therapies.